Carcinogenesis Advance Access published online on May 19, 2005
Carcinogenesis, doi:10.1093/carcin/bgi125
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA
* To whom correspondence should be addressed. TP53 is well-recognized as a mutational target in cancers and common variation in the TP53 gene has been investigated as potentially contributing to cancer susceptibility. The codon 72 polymorphism has been proposed to alter the phenotype of TP53 mutations, and TP53 mutations have been reported to occur preferentially on the arginine allele. Using a consecutive case-series of non-small cell lung cancer we have investigated whether TP53 mutations occur preferentially on the arginine or proline allele, and whether the combination of mutation and allelism confers differences in clinical phenotype. The overall prevalence of TP53 mutation was 26% (76/293). The majority of mutations occurred on the arginine allele (51/60, 85%), and there was corresponding strong selection for loss of the proline allele (87% of LOH events were loss of proline). However, there was no statistically significant difference in the prevalence of mutation by constitutional genotype and among heterozygotes with LOH, TP53 mutation prevalence did not differ by the codon 72 polymorphism (48% on arginine vs 40% on proline). Importantly, patient survival did significantly differ: those patients having a TP53 mutation on the proline allele had the worst survival outcomes (HR=2.6, p<0.03). Further, this phenotype was limited to those patients with advanced disease, where mutation on the proline allele was associated with a significantly worse outcome compared to those without mutation or mutation on the arginine allele (p<0.001). Our data suggest that there are selective pressures for loss of the TP53 proline allele in non-small cell lung cancer. Further, the combination of mutation with the codon 72 proline variant predicts poorer patient survival, particularly in disease that has progressed outside the lung, a finding that warrants further investigation.
Received February 10, 2005
Revised April 14, 2005
Accepted May 10, 2005
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION
TP53 mutation, allelism, and survival in non-small cell lung cancer
2 Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA
Heather H. Nelson, E-mail: hnelson{at}hsph.harvard.edu
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Patocs, L. Zhang, Y. Xu, F. Weber, T. Caldes, G. L. Mutter, P. Platzer, and C. Eng Breast-Cancer Stromal Cells with TP53 Mutations and Nodal Metastases N. Engl. J. Med., December 20, 2007; 357(25): 2543 - 2551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lind, P. O. Ekstrom, D. Ryberg, V. Skaug, T. Andreassen, L. Stangeland, A. Haugen, and S. Zienolddiny Frequency of TP53 Mutations in Relation to Arg72Pro Genotypes in Non Small Cell Lung Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2077 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fukino, L. Shen, A. Patocs, G. L. Mutter, and C. Eng Genomic Instability Within Tumor Stroma and Clinicopathological Characteristics of Sporadic Primary Invasive Breast Carcinoma JAMA, May 16, 2007; 297(19): 2103 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Schwartz, G. M. Prysak, C. H. Bock, and M. L. Cote The molecular epidemiology of lung cancer Carcinogenesis, March 1, 2007; 28(3): 507 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Weber, Y. Xu, L. Zhang, A. Patocs, L. Shen, P. Platzer, and C. Eng Microenvironmental Genomic Alterations and Clinicopathological Behavior in Head and Neck Squamous Cell Carcinoma JAMA, January 10, 2007; 297(2): 187 - 195. [Abstract] [Full Text] [PDF]
|
|